Delhi HC bars Singh brothers from operating accounts in India, Singapore

11 Aug 2018

Delhi High court allows sale of Ranbaxy ex promoter's unencumbered assets

09 May 2018

Delhi HC attaches Ranbaxy promoters’ assets to enforce Daiichi award

26 Feb 2018

The court issued warrants of attachment on the assets of Malvinder Singh and Shivinder Singh, including shares, moveable and immovable property, art as well as debts owed to Oscar Investments and RHC Holding besides asking the Singh brothers to disclose all their assets

Daiichi case: thwarted in SC, Singhs may return to Singapore courts

17 Feb 2018

Brothers Malvinder and Shivinder Singh are “evaluating the option to challenge the ... award in Singapore courts” after the Supreme Court upheld a high court verdict that they must pay Daiichi Sankyo $546 million

Ranbaxy’s Singh bros must pay Daiichi Rs3,500 cr, rules HC

01 Feb 2018

In a petition filed at the Delhi HC, Daiichi had sought to enforce collection of Rs3,500-crore arbitration award it won at a Singapore tribunal in 2016 against Ranbaxy

Ranbaxy ex-bosses to challenge Rs2,562-cr fine for hiding info from Daiichi

06 May 2016

In a majority ruling this week, a three-member arbitration panel in Singapore imposed a fine on the billionaire brothers earlier this week in a case filed by Daiichi Sankyo in 2013

Former Ranbaxy promoters ordered to pay Rs2,500 cr damages

06 May 2016

Daiichi filed an arbitration case in 2013 in Singapore, accusing the Indian promoters of concealment and misrepresentation of facts and seeking compensation for fines that it was forced to pay the US Department of Justice

Sun Pharma sells two Ranbaxy units to Strides Arcolab

21 Sep 2015

Sun, Ranbaxy complete $4-bn merger

24 Mar 2015

On Tuesday, the Reserve Bank of India approved the issue of equity shares of Sun Pharma to non-resident holders of equity shares of Ranbaxy, facilitating the merger through a scheme of arrangement

Sun-Ranbaxy merger deal nears closure with HC nod

09 Mar 2015

Sun Pharma buyout of Ranbaxy gets conditional US nod

31 Jan 2015

Fearing that the $4-billion deal would be anti-competitive, the FTC has stipulated that Sun sell its interest in a generic anti-bacterial medicine

Sun Pharma, Ranbaxy merger deal gets conditional CCI nod

09 Dec 2014

The CCI has asked the two companies to sell off seven brands with combined sales of less than Rs50 crore and market share of 60 to 80 per cent, which the regulator felt, would adversely affect competition

After US, Germany bans Ranbaxy antibiotic from Dewas plant

04 Dec 2014

US court dumps Ranbaxy’s bid to stall launch of rival generics

20 Nov 2014

Ranbaxy’s move is seen as risky especially since the drug maker has been under regulatory probe for a long period now

Ranbaxy sues US FDA over revoking drug approvals

18 Nov 2014

Generic Nexium and Valcyte together would have contributed about $200 million to Ranbaxy's revenue in the first six months of market exclusivity, say analysts

Ranbaxy reports first profit in six quarters with Rs477.75-cr Q2-FY’15 net

28 Oct 2014

Ranbaxy made to pay $40mn to settle pricing litigation in US

16 Oct 2014

Ranbaxy grilled by US Justice Dept over Medicaid drug pricing

18 Sep 2014

The US Justice Department has requested Ranbaxy for documents and information through a civil investigative demand, though it does not allege any wrongdoing

US judge upholds Ranbaxy-Pfizer Lipitor marketing deal

13 Sep 2014

In a piece of good news for the US FDA-challenged Ranbaxy laboratories, a US court has dismissed an anti-trust suit against Pfizer Inc and India's Ranbaxy that accused them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor

Sun Pharma hopes to turn around Ranbaxy in four years of closing deal

12 Sep 2014

Competition panel seeks public comments on Sun-Ranbaxy merger deal

04 Sep 2014

CCI worried about ‘molecular’ effect of Sun-Ranbaxy merger

30 Aug 2014

Sun-Ranbaxy merger: competition panel demands more details

28 Aug 2014

This is probably the first instance where the fair trade watchdog has ordered a public scrutiny of a proposed merger and acquisition deal to ensure compliance to fair trade regulation

Ranbaxy faces fresh US penalty of Rs242 cr over Toansa-made API

22 Aug 2014

This is the second such penalty for the company, which paid $500 million to the US department of justice (DoJ) in May 201

Ranbaxy reports Rs190-cr quarterly loss after settlement with US FDA

30 Jul 2014